StockData
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. (APVO) stock

APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.45−0.02 (-3.25%)

Close on Nov 18, 2026Market cap $803.68KP/E –Yield –

Aptevo Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Aptevo Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$26.89M. For fiscal 2025 it was -$26.31M. The highest annual figure on record is -$21.40M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$26.31M–
FY2024Dec 31, 2024-$24.60M–
FY2023Dec 31, 2023-$28.88M–
FY2022Dec 31, 2022-$28.64M–
FY2021Dec 31, 2021-$21.40M–
FY2020Dec 31, 2020-$27.49M–
FY2019Dec 31, 2019-$40.96M–
FY2018Dec 31, 2018-$51.67M–
FY2017Dec 31, 2017-$53.95M–
FY2016Dec 31, 2016-$138.77M–
FY2015Dec 31, 2015-$61.10M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.44M–
Q1 FY2026Mar 31, 2026-$6.84M–
Q4 FY2025Dec 31, 2025-$6.00M–
Q3 FY2025Sep 30, 2025-$7.61M–
Q2 FY2025Jun 30, 2025-$6.23M–
Q1 FY2025Mar 31, 2025-$6.48M–
Q4 FY2024Dec 31, 2024-$6.38M–
Q3 FY2024Sep 30, 2024-$5.21M–
Q2 FY2024Jun 30, 2024-$6.02M–
Q1 FY2024Mar 31, 2024-$6.98M–
Q4 FY2023Dec 31, 2023-$6.38M–
Q3 FY2023Sep 30, 2023-$6.56M–
Q2 FY2023Jun 30, 2023-$8.18M–
Q1 FY2023Mar 31, 2023-$7.76M–
Q4 FY2022Dec 31, 2022-$7.68M–
Q3 FY2022Sep 30, 2022-$7.78M–
Q2 FY2022Jun 30, 2022-$7.56M–
Q1 FY2022Mar 31, 2022-$5.61M–
Q4 FY2021Dec 31, 2021-$4.04M–
Q3 FY2021Sep 30, 2021-$4.75M–
Q2 FY2021Jun 30, 2021-$5.72M–
Q1 FY2021Mar 31, 2021-$6.89M–
Q4 FY2020Dec 31, 2020-$6.82M–
Q3 FY2020Sep 30, 2020-$6.25M–
Q2 FY2020Jun 30, 2020-$6.81M–
Q1 FY2020Mar 31, 2020-$7.62M–
Q4 FY2019Dec 31, 2019-$7.94M–
Q3 FY2019Sep 30, 2019-$11.46M–
Q2 FY2019Jun 30, 2019-$12.90M–
Q1 FY2019Mar 31, 2019-$11.44M–
Q4 FY2018Dec 31, 2018-$13.59M–
Q3 FY2018Sep 30, 2018-$12.13M–
Q2 FY2018Jun 30, 2018-$12.44M–
Q1 FY2018Mar 31, 2018-$13.50M–
Q4 FY2017Dec 31, 2017-$16.82M–
Q3 FY2017Sep 30, 2017-$10.35M–
Q2 FY2017Jun 30, 2017-$14.65M–
Q1 FY2017Mar 31, 2017-$12.13M–
Q4 FY2016Dec 31, 2016-$14.55M–
Q3 FY2016Sep 30, 2016-$90.53M–

More Aptevo Therapeutics figures

See a number that looks wrong?